This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Achilles' heel a metaphor for a weak point Heel of Italy, the southeast of Italy. after its position in the "boot" Ball of the foot Calcaneal spur heel-bone Callus Hard skin which may cause painful cracks in the heel and sole of the foot Plantar fasciitis High-heeled footwear fashion Squatting position
=== Transcranial direct current stimulation === A 2016 meta-analysis of transcranial direct current stimulation (tDCS) reported some efficacy of tDCS in the treatment of acute depressive disorder with moderate effect size, and low efficacy in treatment-resistant depression, and that use of 2 mA current strength over 20 minutes per day over a short time span can be considered safe.
== Reception and later history == The Guimard entrances received a generally warm reception. Salvador Dalí later called them "those divine entrances to the Métro, by grace of which one can descend into the region of the subconscious of the living and monarchical aesthetic of tomorrow". By way of what became known as le style Métro, they popularized Art Nouveau, which had been a style known largely to connoisseurs of the avant garde. However, critics and many of the public were hostile to the libellules in particular, and criticized the green as "German" and the lettering as "un-French" and, according to critic André Hallays in Le Temps, "confus[ing to] little children who are trying to learn their letters and ... stupefy[ing to] foreigners". On the Champs-Élysées, for example at Marbeuf (now part of Franklin D. Roosevelt), simple stone walls with discreet carved signage were used instead, and a plain design was also used at Bourse. Unhappiness with Guimard's 1904 design for the Opéra station, described in Le Figaro as having "contorted ramps" and "enormous frog-eye lamps", and increasing costs led to the CMP severing its relationship with him. The entrance at Opéra was instead designed by Joseph-Marie Cassien-Bernard, in classical marble. The CMP bought Guimard's molds and rights and a total of 141 of his entrances were ultimately produced, the last in 1913.
This enzyme participates in the pentose phosphate pathway (see image), a metabolic pathway that supplies reducing energy to cells (such as erythrocytes) by maintaining the level of the reduced form of the co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH). The NADPH in turn maintains the level of glutathione in these cells that helps protect the red blood cells against oxidative damage from compounds like hydrogen peroxide. Of greater quantitative importance is the production of NADPH for tissues involved in biosynthesis of fatty acids or isoprenoids, such as the liver, mammary glands, adipose tissue, and the adrenal glands. G6PD reduces NADP+ to NADPH while oxidizing glucose-6-phosphate. Glucose-6-phosphate dehydrogenase is also an enzyme in the Entner–Doudoroff pathway, a type of glycolysis. Clinically, an X-linked genetic deficiency of G6PD makes a human prone to non-immune hemolytic anemia.
National Commission on Terrorist Attacks Upon the United States—Official commission website List of victims September 11, 2001, Documentary Project from the U.S. Library of Congress, Memory.loc.gov September 11, 2001, Web Archive from the U.S. Library of Congress The September 11th Sourcebooks at The National Security Archive September 11 Digital Archive: Saving the Histories of September 11, 2001, from the Center for History and New Media and the American Social History Project/Center for Media and Learning The 9/11 Legacies Project, Oriental Institute, Czech Academy of Sciences, Prague 9/11 at 20: A Week of Reflection; Archived April 16, 2022, at the Wayback Machine, Quincy Institute for Responsible Statecraft September 11, 2001 collection at the Smithsonian National Museum of American History Multimedia
Sources: en.wikipedia.org
Although the demand for fine chemicals on the merchant market has not grown to the extent originally anticipated, fine chemicals still provide opportunities for companies, which are fostering certain critical success factors, namely running fine chemicals as a core business, pursuing niche technologies—primarily biotechnology—and taking advantage of the opportunities offered by the Asian market.
== History == The condition was first described by Austrian ophthalmologist Ernst Fuchs (1851–1930), after whom it is named. In 1910, Fuchs first reported 13 cases of central corneal clouding, loss of corneal sensation and the formation of epithelial bullae, or blisters, which he labeled 'dystrophia epithelialis corneae'. It was characterized by late onset, slow progression, decreased visual acuity in the morning, lack of inflammation, diffuse corneal opacity, intense centrally, and roughened epithelium with vesicle-like features. A shift to the understanding of FECD as primarily a disease of the corneal endothelium resulted after a number of observations in the 1920s. Crystal-like features of the endothelium were noted by Kraupa in 1920, who suggested that the epithelial changes were dependent on the endothelium. Using a slit lamp, Vogt described the excrescences associated with FCD as drop-like in appearance in 1921. In 1924, Graves then provided an extremely detailed explanation of the endothelial elevations visible with slit lamp biomicroscopy. A patient with unilateral epithelial dystrophy and bilateral endothelial changes was described by the Friedenwalds in 1925; subsequent involvement of the second eye led them to emphasize that endothelial changes preceded epithelial changes. As only a subset of patients with endothelial changes proceeded to epithelial involvement, Graves stated on 19 October 1925 to the New York Academy of Medicine that "Fuchs' epithelial dystrophy may be a very late sequel to severer cases of the deeper affection".
Fibrosis, also known as fibrotic scarring, is the development of fibrous connective tissue in response to an injury. Fibrosis can be a normal connective tissue deposition or excessive tissue deposition caused by a disease. Repeated injuries, chronic inflammation and repair are susceptible to fibrosis, where an accidental excessive accumulation of extracellular matrix components, particularly collagen, is produced by fibroblasts, leading to the formation of a permanent fibrotic scar. In response to injury, this is called scarring, and if fibrosis arises from a single cell line, this is called a fibroma. Physiologically, fibrosis acts to deposit connective tissue, which can interfere with or totally inhibit the normal architecture and function of the underlying organ or tissue. Fibrosis can be used to describe the pathological state of excess deposition of fibrous tissue, as well as the process of connective tissue deposition in healing. Defined by the pathological accumulation of extracellular matrix (ECM) proteins, fibrosis results in scarring and thickening of the affected tissue — it is in essence a natural wound healing response which interferes with normal organ function.
== Structure == Reticular fiber is composed of one or more types of very thin and delicately woven strands of type III collagen. These strands build a highly ordered cellular network and provide a supporting network. Many of these types of collagen have been combined with carbohydrate. Thus, they react with silver stains (argyrophilic) and with periodic acid-Schiff reagent but are not demonstrated with ordinary histological stains such as those using hematoxylin. The 1953 Science article mentioned above concluded that the reticular and regular collagenous materials contains the same four sugars – galactose, glucose, mannose, and fucose – but in a much greater concentration in the reticular than in the collagenous material. In a 1993 paper, the reticular fibers of the capillary sheath and splenic cord were studied and compared in the pig spleen by transmission electron microscopy. This paper attempted to reveal their components and the presence of sialic acid in the amorphous ground substance. Collagen fibrils, elastic fibers, microfibrils, nerve fibers, and smooth muscle cells were observed in the reticular fibers of the splenic cord. On the other hand, only microfibrils were recognized in the reticular fibers of the capillary sheath. The binding of LFA lectin to the splenic cord was stronger than the capillary sheath. These findings suggested that the reticular fibers of the splenic cord include multiple functional elements and might perform an important role during contraction or dilation of the spleen.
=== Multidisciplinary approach === Given the systemic nature of many autoimmune disorders, a multidisciplinary approach may be necessary for their diagnosis and management. This can involve rheumatologists, endocrinologists, gastroenterologists, neurologists, dermatologists, and other specialists, depending on the organs or systems affected by the disease. In summary, the diagnosis of autoimmune disorders is a complex process that requires a thorough evaluation of clinical, laboratory, and imaging data. Due to the diverse nature of these diseases, an individualized approach, often involving multiple specialists, is crucial for an accurate diagnosis.
Sources: en.wikipedia.org
Krypton (from Ancient Greek: κρυπτός, romanized: kryptos 'the hidden one') is a chemical element; it has symbol Kr and atomic number 36. It is a colorless, odorless noble gas that occurs in trace amounts in the atmosphere and is often used with other rare gases in fluorescent lamps. Krypton is chemically inert. Krypton, like the other noble gases, is used in lighting and photography. Krypton light has many spectral lines, and krypton plasma is useful in bright, high-powered gas lasers (krypton ion and excimer lasers), each of which resonates and amplifies a single spectral line. Krypton fluoride also makes a useful laser medium. From 1960 to 1983, the official definition of the metre was based on the wavelength of one spectral line of krypton-86, because of the high power and relative ease of operation of krypton discharge tubes.
=== Venom === Rattlesnake venom is hemotoxic, destroying tissue, causing necrosis and coagulopathy (disrupted blood clotting). In the U.S., the tiger rattlesnake (C. tigris) and some varieties of the Mojave rattlesnake (C. scutulatus) also have a presynaptic neurotoxic venom component known as Mojave type A toxin, which can cause severe paralysis. However, most North American rattlesnakes are not neurotoxic. Although it has a comparatively low venom yield, the venom toxicity of C. tigris is considered to be among the highest of all rattlesnake venoms, and among the highest of all snakes in the Western Hemisphere based on LD50 studies conducted on laboratory mice. C. scutulatus is also widely regarded as producing one of the most toxic snake venoms in the Americas, based on LD50 studies in laboratory mice. Rattlesnake venom is a mixture of five to fifteen enzymes, various metal ions, biogenic amines, lipids, free amino acids, proteins, and polypeptides. More specifically, there are three main families of toxins in rattlesnakes: phospholipases A2 (PLA2s), snake venom metalloproteinases (SVMPs), and snake venom serine proteinases (SVSPs). It contains components meant to immobilize and disable the prey, as well as digestive enzymes, which break down tissue to prepare for later ingestion. The venom is very stable, and retains its toxicity for many years in storage. Snake venom, in general, has a complex and ongoing evolutionary process, and rattlesnake venom is no different. The primary mechanisms of evolution are both gene duplication and gene loss events.
=== Economic policies === On taking control of the Xikang region, Liu Wenhui noted the poverty of the area, stating of the native population: "They lack clothes to cover their bodies and food to fill their bellies. The people suffer through life without any joy in living." Liu made efforts to reduce the tax burden on the people, slashing levies by 30% to 50% for many counties in Xikang. However, the problem of funding Liu's army was still a major one, as Liu had been forced out of his productive Sichuan basin territories. In 1934, the government mainly still relied on taxes, but from 1935 onwards Liu's administration had a monthly stipend from the central government worth 15,000 yuan per month. He had also managed to increase the amount of grain tax collected from 1,509 Sichuanese dan in 1932 to 13,352 dan in 1939.
== Career and research == After receiving her Ph.D in biochemestry and molecular biology, Babady then completed her post doctoral in clinical microbiology. Since 2011, Babady has worked at the Memorial Sloan Kettering Cancer Center, serving as chief of its Clinical Microbiology Service since April 2021 and Director of its Clinical Microbiology Fellowship Program. Her research has largely focused on diagnostic microbiology in immunocompromised hosts. In early 2020, Babady developed the first Food and Drug Administration-authorized COVID-19 test used in New York City. Her team also developed a saliva test with sensitivity matching nasopharyngeal swabs, minimizing exposure to healthcare workers. In recognition of her work, Babady was named on Crain's New York Business' 2021 Empire BCBS Whole Health Heroes list. In 2019, Babady was elected as a fellow of the Infectious Diseases Society of America. In June 2019, she became the inaugural co-chair of the Fungal Diagnostics Laboratory Consortium. In February 2021, she was elected as a fellow of the American Academy of Microbiology. In July 2022, Babady was appointed President of the Pan American Society for Clinical Virology for a two-year term. In 2021, Babady began a five-year term as a Senior Editor for the academic journal Microbiology Spectrum and currently serves on the editorial boards of The Journal of Molecular Diagnostics and Journal of Clinical Virology. In July 2023, Babady began a four-year term on the Centers for Disease Control and Prevention's Clinical Laboratory Improvement Advisory Committee.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.